Other Consolidated Financial Statement Detail

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In millions)	2015			2014			2015			2014
Interest income	$	5.4		$	3.6		$	13.0		$	8.7
Interest expense	(15.6		)	(7.4		)	(28.1		)	(22.1		)
Gain (loss) on investments, net	1.1			(3.1		)	(0.3		)	13.5
Foreign exchange gains (losses), net	(4.3		)	(4.8		)	(18.8		)	(9.5		)
Other, net	(2.0		)	(4.6		)	(7.1		)	(7.6		)
Total other income (expense), net	$	(15.4	)	$	(16.3	)	$	(41.3	)	$	(17.0	)

Accrued Expenses and Other

Accrued expenses and other consists of the following:



(In millions)	As of September 30, 2015		As of December 31, 2014
Current portion of contingent consideration obligations	$	479.5	$	265.5
Revenue-related rebates	462.7		359.2
Employee compensation and benefits	214.2		393.8
Royalties and licensing fees	154.9		172.4
Deferred revenue	58.4		120.9
Other	549.2		507.5
Total accrued expenses and other	$	1,918.9	$	1,819.3

Other Long-Term Liabilities

Other long-term liabilities consist of the following:



(In millions)	As of September 30, 2015		As of December 31, 2014
Contingent consideration obligations	$	301.9	$	200.0
Employee compensation and benefits	218.4		200.7
Other	341.1		249.4
Total other long-term liabilities	$	861.4	$	650.1

Pricing of TYSABRI in Italy - AIFA

In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary, received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit is unenforceable. That appeal is pending.

In June 2014, AIFA eliminated the reimbursement limit from February 2013 going forward. As a result, in June 2014, we recognized $53.5 million of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL continue to discuss a possible resolution for the period between February 2009 and January 2013. We have approximately EUR75 million recorded as accrued expenses and deferred revenue in our long-term liabilities in our condensed consolidated balance sheets for this matter.

For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 4, Accounts Receivable to our consolidated financial statements included in our 2014 Form 10-K.